Government Decree No. 454 / 2009 Coll.
Ordinance of the Government establishing for the purposes of the Criminal Code what is considered as anabolic and other hormonal substances and what is their greater quantity and what is considered as a method for the purposes of the Criminal Code to increase oxygen transmission in the human organism and other methods with doping effect
Valid
Regulation
Effective from 01.01.2010
Zobrazeno prvních 200 z celkem 254 ustanovení tohoto předpisu.
Zobrazit celý předpis →
Pro stažení celého znění použijte tlačítko Stáhnout výše.
454
GOVERNMENT REGULATION
of 7 December 2009
establishing, for the purposes of the Criminal Code, what is considered as anabolic and other hormonal substances and what is the greater quantity of them and what is considered as a method for the purposes of the Criminal Code to increase oxygen transmission in the human organism and other methods with doping effect
The Government orders pursuant to § 289 (4) of Act No. 40 / 2009 Coll., criminal code:
Substances listed in Annex 1 to this Regulation shall be considered as having anabolic and other hormonal effects within the meaning of Section 288 of the Criminal Code.
For substances with anabolic and other hormonal effects within the meaning of Section 288 of the Penal Code, more than one blister, injection or similar normally indivisible packaging of the drug containing these substances or similar quantities of these substances in a special doping preparation is understood to mean more than one blister.
The methods set out in Annex 2 to this Regulation shall be considered as a method of increasing oxygen transmission in the human organism and as other methods having a doping effect within the meaning of Section 288 of the Criminal Code.
This Regulation shall enter into force on 1 January 2010.
Prime Minister:
Ing. Fischer, CSc.
Minister of Justice:
JUDr. Kovářová v. r.
Příloha č. 1
Annex No. 1 to Government Decree No. 454 / 2009 Coll.
Anabolic and other hormonal agents
A. ANABOLIC SUBSTANCES
A.1 Androgenic anabolic steroids (AAS)
(a) exogenous AAS
1.1-androstenediol (5a-androst-1-en-3b, 17b-diol);
2.1-androstendione (5a-androst-1-en-3,17-dione);
3.1-testosterone (17b-hydroxy-5a-androst-1-en-3-one);
4.4-hydroxytestosterone (4,17b-dihydroxyandrost-4-en-3-one);
5.19-norandrostendione (estr-4-en-3,17-dione);
6. bolandiol (19-norandrostendiol);
7. Bolasterone;
8. boldenone;
9. boldione (androsta-1,4-dien-3,17-dione);
10. danazol (17aethenyl-17b- hydroxyandrost-4-eno [2,3-d] isoxazole);
11. dehydrochloromethyl testosterone (4-chloro-17b-hydroxy-17a-methylandrosta-1,4-dien-3one);
12. desoxymethyltestosterone (17amethyl-5a-androst-2-en-17bol);
13. Drostanolone;
14. estra-4,9-dien-3,17-dione (19-norandrosta-4,9-dien-3,17-dione);
15. ethyl estrenol (19-nor-17a-pregn-4-en-17-ol);
16. fluoxymesterone;
17. formebolone;
18. furazabol (17b-hydroxy-17a-methyl-5a-androstano [2,3-c] -furazan);
19. Gestrinone;
20. calusterone;
21. clostebol;
22. mestanolone;
23. mesterolone;
24. methanedienone (17b- hydroxy- 17a- methylandrosta-1,4-dien-3-one);
25. Methandriol;
26. methasterone (2a, 17adimethyl-5a-androstan-3-one-17bol);
27. methenolone;
28. methyl-1-testosterone (17b-hydroxy-17a-methyl-5-androst-1-en-3-one);
29. methyldienolone (17b- hydroxy- 17a- methyl-4,9-dien-3-one);
30. methylnortestosterone (17b- hydroxy- 17a-methyl-str-4-en-3-one);
31. methyltestosterone;
32. methyltrienolone (17b- hydroxy- 17a- methyl-4,9,11-trien-3-one);
33. mibolerone;
34. nandrolone;
35th norboletone;
36. norclostebol;
37. norethandrolone;
38. oxabolone;
39. oxandrolone;
40. oxymesterone;
41. oxymetholone;
42. prostanozole ([3,2-c] pyrazol-5a-etioallocholan-17btetrahydropyranol);
43rd quinbolone;
44. stanozolol;
45. stenbolone;
46. tetrahydrogestrinone (18ahomopregna-4,9,11-trien--17bol-3-one);
47th Trenbolone;
48. other substances with similar chemical structure or similar biological effects;
(b) endogenous AAS
1.4-androstendiol (androst-4-en-3b, 17b-diol);
2.5-androstendione (androst-5-en-3, 17-dione);
3.19-norandrosterone;
4.19-noretiocholanolone;
5.
6.3b-hydroxy-5a-androstan-17-one;
7.5aandrostan-3a, 17adiol;
8.5.a.androstan-3a, 17b-diol;
9.5aandrostan-3b, 17adiol;
10.5aandrostan-3b, 17bdiol;
11. androst-4-en-3a, 17adiol;
12. androst-4-en-3a, 17b-diol;
13. androst-5-en-3a, 17adiol;
14. androst-5-en-3a, 17b-diol;
15. androst-5-en-3b, 17adiol;
16. androstendiol (androst-5-en-3b, 17b-diol);
17. androstendione (androst-4-en-3, 17-dione);
18. Dihydrotestosterone;
19. Epidihydrotestosterone;
20. Prasterone (dehydroepiandrosterone DHEA);
21. testosterone;
22. other substances with similar chemical structure or similar biological effects.
A.2 Other anabolic agents
1. clenbuterol;
2. selective androgen receptor modulators (SARM), for example:
2.1 ligandrole (LGD-40233);
2.2 S- 23;
3. tibolone;
4. zeranol;
5. zilpaterol;
6. other substances with similar chemical structure or similar biological effects.
B. PEPTIDE HORMONES, GROWTH FACTORS, COMPOUNDS AND MIMETIC
erythropoiesis stimulating agents
(a) erythropoietin receptor agonists such as:
1. darbepoetins (dEPO);
2. erythropoietins (EPO);
3. compounds based on EPO, for example:
3.1 EPO-Fc;
3.2 methoxypolyethylene glycol-epoetin beta (CERA);
4. EPO- mimetic agents and their compounds, for example:
4.1 ARA-290 (cibinetide);
4.2. CNTO 530;
4.3. Peginesatide;
(b) the activation means of the factor-inducing hypoxia (HIF), such as:
1. daprodustat (GSK1278863);
2. IOX2 molidustat (BAY 85-3934);
3. roxadustat (FG-4592);
4. vadudustat (AKB-6548);
(c) GATA inhibitors, such as:
1. K-11706;
(d) transforming growth factor beta (TGF - β) signaling inhibitors such as:
1. lupatercept;
2. sotatercept.
B.2 Peptide hormones and their release factors
(a) choriogonadotropin (CG) and luteinisation hormone (LH) and their release factors
1. buserelin;
2. deslorelin;
3. gonadoreline;
4. goserelin;
5. leuprorelin;
6. nafarelin;
7. triptorelin;
(b) corticosteroids, their release factors;
(c) growth hormone (GH), its fragments and release factors
1. growth hormone fragments, for example:
1.1 AOD- 9604;
1.2 hGH 176-191;
2. Growth hormone release hormone (GHRH) and its analogues, such as:
2.1 CJC-1293;
2.2 CJC-1295;
2.3. CJC-1295 DAC;
2.4. Dumorelin;
2.5 rismorelin;
2.6 sermorelin;
2.7 somatorelin;
2.8. Tesamorelin;
(d) growth hormone secretion (GHS) and ghrelin receptor agonists, such as:
1. anamorelin;
2. ibutamoren (MK-677);
3. ipamorelin (NNC 26-0161);
4. lenomorelin (ghrelin);
5. macimorelin;
6. tabimorelin;
(e) releasing peptides of growth hormone GH (GHRP), such as:
1. alexamorelin;
2. examorelin (hexarelin);
3.GHRP-1;
4.GHRP-2 (pralmorelin);
5.GHRP-3;
6. GHRP-4;
7. GHRP-5;
8.GHRP-6;
(f) releasing gonadoliberin peptides (GnRH), for example:
1. kisspeptin;
(g) other substances with similar chemical structure or similar biological effects.
Growth factors and growth factor modulators
(a) fibroblaster growth factors (FGF);
(b) hepatocyte growth factor (HGF), such as:
1. dihexa (PNB-0408);
(c) insulin similar to growth factor-1 (IGF-1) and its analogues;
(d) mechanical growth factors (MGF);
(e) platelet growth factor (PDGF);
(f) thymosine-β4 and its derivatives, such as:
1. TB-500;
2. thymosine α1 (thymalfasin);
(g) vascular-endothelial growth factor (VEGF);
(h) other substances with similar chemical structure or similar biological effects.
C. HORMON AND METABOLIC MODULATORS
C.1 Flavourings inhibitors
1. aminoglutethimide;
2. Anastrozole;
3. exemestane;
4. formestane;
5.
6. testosterone;
7. other substances with similar chemical structure or similar biological effects.
C.2 Selective oestrogen receptor modulators (SERM)
1. raloxifene;
2. Tamoxifene;
3. toremifene;
4. other substances with similar chemical structure or similar biological effects.
Sign in for notes, favorites and notifications
Regulation Information
| Citation | Government Regulation No. 454 / 2009 Coll., establishing, for the purposes of the Criminal Code, what is considered to be substances with anabolic and other hormonal effects and what is the greater quantity of them, and what is considered to be a method for the purposes of the Criminal Code to increase oxygen transmission in the human organism and other methods with doping effect |
|---|---|
| Regulation Type | Regulation |
| Author | - |
| Collection | Code of Laws |
| Date of Promulgation | 22.12.2009 |
|---|---|
| Effective from | 01.01.2010 |
| Effective until | - |
| Status | Valid |
The regulation text is for informational purposes only.
Comments 0